Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01336686 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
NCT01336686: Completed Phase 2 study, sponsored by Gilead Sciences.
NCT01336686 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 67 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01336686, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety and effectiveness of MBX-102 compared to placebo when given orally once daily for 4 weeks for the treatment of hyperuricemia in patients with gout.
Interventions
- DRUG Colchicine
- DRUG Placebo comparator
- DRUG Arhalofenate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2011-05 |
| Est. Completion | 2011-11 |
| Phase | Phase 2 |
What the finished NCT01336686 record still lists
NCT01336686 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 67 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 3 interventions - of which Colchicine is the first listed.
NCT01336686 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01336686 about?
NCT01336686 is a clinical study titled "Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout". The purpose of the study is to evaluate the safety and effectiveness of MBX-102 compared to placebo when given orally once daily for 4 weeks for the treatment of hyperuricemia in patients with gout.
What is the current status of trial NCT01336686?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2011-05. Estimated completion is 2011-11.
What interventions are being tested in trial NCT01336686?
The interventions under investigation include: Colchicine (DRUG), Placebo comparator (DRUG), Arhalofenate (DRUG).
Who is sponsoring clinical trial NCT01336686?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01336686's enrollment target sits among peer trials
67 974th of 2000 higher than 1,026 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia